Neuraxis

Neuraxis Receivables/Revenue

The Receivables to Revenue Ratio of Neuraxis (NRXS) as of Nov 22, 2026 is 9.11 %. In the previous year, Receivables to Revenue Ratio was 2.98 % — a change of 206.05% (higher).

Receivables/Revenue

9.11 %

YoY

206.05%

Last updated:

Receivables to Revenue Ratio of Neuraxis is 2024 9.11 % . Receivables to Revenue Ratio of Neuraxis was 2023 2.98 % . It decreases by 206.05% higher compared to the previous year.

The Neuraxis Receivables/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables/Revenue
Date
Receivables/Revenue
Jan 1, 2020
16.06 USD
Jan 1, 2021
4.41 USD
Jan 1, 2022
6.33 USD
Jan 1, 2023
2.98 USD
Jan 1, 2024
9.11 USD
The Neuraxis Receivables/Revenue history
YEARReceivables/RevenueYoY
9.11 %+206.05%
2.98 %-53.01%
6.33 %+43.60%
4.41 %-72.54%
16.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuraxis Stock analysis

What does Neuraxis do? NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market. Neuraxis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuraxis stock

Receivables to Revenue Ratio of Neuraxis is 9.11 % in 2024.

Receivables to Revenue Ratio of Neuraxis changed from 2.98 % to 9.11 %, representing a 206.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Receivables to Revenue Ratio Neuraxis since 2006 – with annual values, charts, and detailed analysis.

The Receivables/Revenue ratio shows what percentage of annual revenue is tied up in accounts receivable. Rising ratios may signal collection issues.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Receivables to Revenue Ratio's Neuraxis with sector peers and the industry average to assess whether it is attractive.

To evaluate Receivables to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Receivables to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Neuraxis

All Key Metrics — Neuraxis